Лекарственное лечение метастазов тройного негативного рака молочной железы О. В. Смирнова , 2, В. И. Борисов 1, Л. З. Вельшер 1 гбуз «Онкологический клинический диспансер №1»
жүктеу/скачать 183,23 Kb. Pdf көрінісі
|
Onkologia 2015 06 074 2
| Clin Oncol
. 2007;25(18):1086. 38. Yi S, Uhm J, Cho E et al. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. Int J Cancer. 2009;124(6):1457-1462. doi:10.1002/ijc.24090. 39. Von Minckwitz G, Schneeweiss A, Salat C et al. A randomized phase II trial investigating of addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Lancet Oncol. 2014;15(7):747-756. doi:10.1016/s1470-2045(14)70160-3. 40. Isakoff SJ, He L, Mayer EL et al. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. J Clin Oncol. 2014:32(5, Suppl.):abstr.1020. (ASCO Annual Meeting). 41. Rivera E, Lee J, Davies A et al. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist. 2008;13(12):1207-1223. doi:10.1634/theoncologist.2008-0143. 42. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer (ABC1). The Breast. 2012;2(3):242-252. doi:10.1016/j.breast.2012.03.003. 43. Cinieri S, Chan A, Altundag K et al. Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial). J Clin Oncol. 2014;32(5,Suppl.):abstr.1044. (ASCO Annual Meeting). 44. Wang J, Xu B, Yuan P, Ma F, Li Q, Zhang P et al. Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial. Cancer. 2015;121(19):3412-3421. doi:10.1002/cncr.29492. 45. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 2004;9(6):617-632. doi:10.1634/theoncologist.9-6-617. 46. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921. doi:10.1038/nature03445. 47. O`Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple- negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol. 2009;27(15,Suppl.):18s, abstr.3. doi:10.1016/s1359-6349(09)72040-3. 48. O`Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med . 2011;364(3):205-214. doi:10.1056/nejmoa1011418. 49. Cotter MB, Pierce A, McGowan PM et al. PARP1 in triple- negative breast cancer: expression and therapeutic potencial. J Clin Oncol. 2011;29(Suppl.):abstr.1061. (ASCO Annual Meeting. June 3-7, Chicago 2011). 50. Liu JF, Tolaney SM, Birrer M et al. A Phase 1 trial of the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breat cancer. Eur J Cancer . 2013;49(14):2972-2978. doi:10.1016/j.ejca.2013.05.020. 51. Somlo G. Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96. J Clin Oncol. 2014;32(5,Suppl.):abstr.1021. (ASCO Annual Meeting). 52. Linderholm BK, Hellborg H, Johansson U et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple- negative breast cancer. Ann Oncol. 2009;20(10):1639-1646. doi:10.1093/annonc/mdp062. 53. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676. doi:10.1056/nejmoa072113. 54. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239-3247. doi:10.1200/jco.2008.21.6457. 55. O`Shaughnessy J, Dieras V, Glaspy K et al. Comparison of subgroup analyses of PTS from the three phase III studies of Avastin in combination with chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Res. 2009;69(24,Suppl.):abstr.207. doi:10.1158/0008-5472.sabcs-09-207. 56. Brufsky A, Valero V, Tiangco B et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple- negative breast cancer (TNBC): analysis of RIBBON-2. Breast жүктеу/скачать 183,23 Kb. Достарыңызбен бөлісу:
|